Located in Milwaukee, Wisconsin, the Versiti Blood Research Institute (VBRI) is the largest blood-focused research institute in the United States. With over 30 basic, translational, and clinical investigators, the institute is dedicated to advancing scientific knowledge and developing innovative therapies related to blood and blood disorders. The institute's research interests encompass a wide range of topics, including transfusion medicine, cellular therapy, thrombosis/hemostasis, immunology, and hematologic malignancies. As a vital part of Versiti, a non-profit organization with a blood bank at its core, the VBRI strives to improve lives through innovative research and the development of novel diagnostics and treatments.
VBRI is part of the Milwaukee Regional Medical Campus, a rapidly growing clinical-translational research hub. VBRI’s proximity to the Medical College of Wisconsin, Childrens’ Hospital of Wisconsin, and Froedtert Hospital facilitates seamless interdisciplinary collaborations. A range of exemplary core facilities support highly competitive research. In the summer of 2024, construction of a new research building began, doubling existing VBRI research space to enable the recruitment of 10-15 new faculty. With its renowned researchers, strategic expansion plans and location in a highly collaborative environment, the VBRI is poised to maintain and expand its position as one of the leading hematology institutes in the world.
Under the direction of a Principal Investigator, further develops and expands understanding of scientific theory in his/her area of interest. Incumbent also learns and applies scientific laboratory techniques and gains experience in other areas of research that will lead to increased probability of success as an independent scientist. This is a training position with an expected duration of 1 – 3 years.
The Pulikkan Lab focuses on uncovering the mechanisms of leukemogenesis and identifying novel therapeutic targets in CEBPA mutant and inv(16) acute myeloid leukemia (AML). Recently, the lab developed the first conditional knock-in mouse model for CEBPA mutations in AML. Successful candidates will work on projects related to the therapeutic targeting of chromatin deregulation in CEBPA-mutant AML. These projects include in vivo leukemic studies (using genetic and patient-derived xenograft mouse models), CRISPR genome editing, in vitro differentiation, flow cytometry, and multi-omics approaches (ATAC-seq, CUT&Tag, RNA-seq, Hi-C).
The position offers impactful publication opportunities, participation at international conferences, a competitive salary, and excellent career development prospects. It is supported by an NIH National Cancer Institute (NCI) R01 grant recently awarded to the Pulikkan Lab. The role seeks a highly motivated, energetic, research-focused individual with a Ph.D. in Cancer Biology, Genetics, Biochemistry, or a related field. Successful candidates must have a proven track record of productivity and research experience and should be willing to work with mouse models.
Education
Experience
Knowledge, Skills and Abilities
Tools and Technology
#LI-EH1
#LI-Onsite
#VBRI